Perrigo Company PLC (PRGO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $2.25B
Last updated: Nov 17, 2026 at 11:06 AM ET
Perrigo Company PLC (PRGO) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Perrigo Company reported EPS of $0.60, above the $0.56 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PRGO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
PRGO Earnings Call
The latest PRGO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, PRGO beat 26, missed 12 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $988.60M, down 4.9% from $1.04B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.60 | $0.56 | $0.50 - $0.58 | +7.14% | Beat | -25.0% | 3 | 0 up, 3 down | Nov 4, 2026 | $988.60M |
| Jun 30, 2026 | $0.50 | $0.31 | N/A | +61.29% | Beat | -12.3% | 4 | 0 up, 3 down | Aug 5, 2026 | $1.02B |
| Mar 31, 2026 | $0.43 | $0.31 | $0.23 - $0.36 | +38.71% | Beat | -28.3% | 3 | 0 up, 1 down | May 6, 2026 | $969.20M |
| Dec 31, 2025 | $0.77 | $0.80 | N/A | -3.75% | Miss | +113.9% | 3 | 0 up, 1 down | Feb 26, 2026 | $1.11B |
| Sep 30, 2025 | $0.80 | $0.75 | $0.74 - $0.82 | +6.67% | Beat | -1.2% | 4 | 0 up, 1 down | Nov 5, 2025 | $1.04B |
| Jun 30, 2025 | $0.57 | $0.59 | $0.55 - $0.62 | -3.39% | Miss | +7.5% | 3 | 0 up, 3 down | Aug 6, 2025 | $1.06B |
| Mar 31, 2025 | $0.60 | $0.57 | $0.52 - $0.57 | +5.26% | Beat | +106.9% | 4 | 1 up, 0 down | May 7, 2025 | $1.04B |
| Dec 31, 2024 | $0.36 | $0.95 | $0.87 - $0.95 | -62.11% | Miss | -58.1% | 4 | 0 up, 1 down | Feb 27, 2025 | $1.14B |
| Sep 30, 2024 | $0.81 | $0.81 | $0.80 - $0.83 | 0.00% | In line | +26.6% | 4 | 0 up, 1 down | Nov 6, 2024 | $1.09B |
| Jun 30, 2024 | $0.53 | $0.46 | $0.40 - $0.49 | +15.22% | Beat | -15.9% | 3 | 0 up, 0 down | Aug 2, 2024 | $1.07B |
| Mar 31, 2024 | $0.29 | $0.23 | $0.23 - $0.23 | +26.09% | Beat | -35.6% | 3 | 0 up, 0 down | May 7, 2024 | $1.08B |
| Dec 31, 2023 | $0.86 | $0.83 | $0.78 - $0.87 | +3.61% | Beat | +14.7% | 3 | 0 up, 0 down | Feb 27, 2024 | $1.16B |
| Sep 30, 2023 | $0.64 | $0.63 | $0.59 - $0.64 | +1.59% | Beat | +14.3% | 2 | 0 up, 0 down | Nov 7, 2023 | $1.12B |
| Jun 30, 2023 | $0.63 | $0.51 | $0.50 - $0.51 | +23.53% | Beat | +46.5% | 2 | 0 up, 0 down | Aug 8, 2023 | $1.19B |
| Mar 31, 2023 | $0.45 | $0.43 | $0.39 - $0.44 | +4.65% | Beat | +36.4% | 3 | 0 up, 1 down | May 9, 2023 | $1.18B |
| Dec 31, 2022 | $0.75 | $0.71 | N/A | +5.63% | Beat | +25.0% | 2 | 0 up, 0 down | Feb 27, 2023 | $1.16B |
| Sep 30, 2022 | $0.56 | $0.67 | $0.62 - $0.74 | -16.42% | Miss | +24.4% | 4 | 0 up, 0 down | Nov 8, 2022 | $1.10B |
| Jun 30, 2022 | $0.43 | $0.44 | $0.43 - $0.47 | -2.27% | Miss | -14.0% | 3 | 0 up, 1 down | Aug 9, 2022 | $1.12B |
| Mar 31, 2022 | $0.33 | $0.42 | $0.41 - $0.43 | -21.43% | Miss | -34.0% | 3 | 0 up, 1 down | May 11, 2022 | $1.07B |
| Dec 31, 2021 | $0.60 | $0.56 | N/A | +7.14% | Beat | -35.5% | N/A | 0 up, 0 down | Mar 1, 2022 | $1.10B |
| Sep 30, 2021 | $0.45 | $0.65 | $0.63 - $0.67 | -30.77% | Miss | -51.6% | 3 | N/A | Nov 10, 2021 | $1.04B |
| Jun 30, 2021 | $0.50 | $0.61 | $0.57 - $0.66 | -18.03% | Miss | -51.5% | 5 | N/A | Aug 11, 2021 | $981.10M |
| Mar 31, 2021 | $0.50 | $0.57 | $0.52 - $0.62 | -12.28% | Miss | -56.1% | 7 | N/A | May 11, 2021 | $1.01B |
| Dec 31, 2020 | $0.93 | $1.00 | $0.94 - $1.06 | -7.00% | Miss | -12.3% | 8 | N/A | Mar 1, 2021 | $1.29B |
| Sep 30, 2020 | $0.93 | $0.86 | $0.78 - $0.89 | +8.14% | Beat | -10.6% | 8 | N/A | Nov 4, 2020 | $1.00B |
| Jun 30, 2020 | $1.03 | $0.87 | $0.73 - $1.01 | +18.39% | Beat | +19.8% | 8 | N/A | Aug 5, 2020 | $948.80M |
| Mar 31, 2020 | $1.14 | $1.04 | $0.73 - $1.13 | +9.62% | Beat | +6.5% | 9 | N/A | Apr 30, 2020 | $1.08B |
| Dec 31, 2019 | $1.06 | $1.06 | $0.90 - $1.14 | 0.00% | In line | +9.3% | 10 | N/A | Feb 27, 2020 | $1.32B |
| Sep 30, 2019 | $1.04 | $0.94 | $0.81 - $0.99 | +10.64% | Beat | -4.6% | 11 | N/A | Nov 6, 2019 | $1.19B |
| Jun 30, 2019 | $0.86 | $0.80 | $0.72 - $0.91 | +7.50% | Beat | -29.5% | 11 | N/A | Aug 8, 2019 | $1.15B |
| Mar 31, 2019 | $1.07 | $0.93 | $0.60 - $1.17 | +15.05% | Beat | -15.1% | 10 | N/A | May 8, 2019 | $1.17B |
| Dec 31, 2018 | $0.97 | $1.00 | $0.87 - $1.06 | -3.00% | Miss | -24.2% | 11 | N/A | Feb 27, 2019 | $1.20B |
| Sep 30, 2018 | $1.09 | $1.04 | $0.80 - $1.10 | +4.81% | Beat | -21.6% | 12 | N/A | Nov 8, 2018 | $1.13B |
| Jun 30, 2018 | $1.22 | $1.20 | $1.12 - $1.30 | +1.67% | Beat | 0.0% | 16 | N/A | Aug 9, 2018 | $1.19B |
| Mar 31, 2018 | $1.26 | $1.14 | $1.01 - $1.22 | +10.53% | Beat | +20.0% | 17 | N/A | May 8, 2018 | $1.22B |
| Dec 31, 2017 | $1.28 | $1.25 | $1.12 - $1.36 | +2.40% | Beat | -22.4% | 17 | N/A | Mar 1, 2018 | $1.28B |
| Sep 30, 2017 | $1.39 | $1.11 | $0.94 - $1.18 | +25.23% | Beat | -15.8% | 16 | N/A | Nov 9, 2017 | $1.23B |
| Jun 30, 2017 | $1.22 | $0.92 | $0.80 - $1.05 | +32.61% | Beat | -36.8% | 14 | N/A | Aug 10, 2017 | $1.24B |
| Mar 31, 2017 | $1.05 | $0.99 | $0.93 - $1.04 | +6.06% | Beat | -40.0% | 14 | N/A | May 22, 2017 | $1.19B |
| Dec 31, 2016 | $1.65 | $1.81 | $1.66 - $1.87 | -8.84% | Miss | -8.3% | 14 | N/A | Feb 27, 2017 | $1.06B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.74, up 37.7% from the year before. It was $6.98 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.74 | +37.7% |
| Dec 31, 2024 | $1.99 | -22.9% |
| Dec 31, 2023 | $2.58 | +24.6% |
| Dec 31, 2022 | $2.07 | N/A |
| Dec 31, 2021 | $2.05 | -49.1% |
| Dec 31, 2020 | $4.03 | N/A |
| Dec 31, 2019 | $4.03 | -11.2% |
| Dec 31, 2018 | $4.54 | -8.1% |
| Dec 31, 2017 | $4.94 | -29.2% |
| Dec 31, 2016 | $6.98 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,200 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,236 | 7 | |
| 2026Q2 | Jun 30, 2026 | 5,981 | 7 | |
| 2026Q1 | Mar 31, 2026 | 5,211 | 8 | |
| 2025Q4 | Dec 31, 2025 | 5,522 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,145 | 7 | |
| 2025Q2 | Jun 30, 2025 | 6,708 | 7 | |
| 2025Q1 | Mar 31, 2025 | 6,245 | 8 | |
| 2024Q4 | Dec 31, 2024 | 15,850 | 14 |
2026Q3 Earnings Call
Opening remarks
Eric Jacobson Vice President, Global Investor Relations Good morning and good afternoon, everyone. Welcome to Perrigo's third quarter 2026 earnings conference call. A copy of the release we issued today and the accompanying presentation are available within the Investors section of the perrigo.com website. Joining today's call are Perrigo's Interim President and CEO, Albert Manzone, and CFO, Eduardo Bezerra. As a reminder, we recently announced an agreement to divest our infant formula business. Beginning with the fourth quarter and full year 2026 reporting, the infant formula business will be reported as discontinued operations. Accordingly, the company's all-in outlook no longer includes infant formula. The company's core outlook continues to exclude infant formula and previously announced divestitures. During this presentation, participants will make certain forward-looking statements. Please refer to the slides for information regarding these statements, which are subject to important risks and uncertainties. We will reference adjusted financial measures that are non-GAAP in nature. See the appendix to the earnings presentation for additional details and reconciliations of all non-GAAP to GAAP financial measures presented. Moving to the agenda. Albert will begin with his perspective on Perrigo and the priorities he has identified. He will then discuss our third quarter performance, progress against the Three-S plan, and the commercial opportunities he sees to drive stronger, more consistent growth. Eduardo will then provide a financial review and discuss our 2026 outlook. With that, I'll turn it over to Albert.
Albert Manzone Interim President and CEO Thanks, Eric. Good morning, good afternoon, and thank you for joining today's call. Over my first five months at Perrigo, I have spent a significant amount of time listening to our customers, our consumers, and our people, digging into the business and our capabilities, and developing a deeper understanding of what we do well and where we can be better. And I have been increasingly impressed. We have leading store brand products, strong brands, attractive positions across our categories, and a talented organization that knows the consumer self-care business exceptionally well. I want to thank our teams across Perrigo for their hard work, commitment, and the way they have welcomed me. At the same time, it has become clear why those strengths have not translated consistently into the results we should be delivering. Over time, Perrigo has become too complex. The business has not been integrated to the degree it needs to be, and that complexity has made it harder for our teams to execute with the necessary speed and focus. We are taking decisive action to simplify and strengthen Perrigo, and that process is a major focus for me. That means being extremely deliberate about where we invest, the businesses and geographies where we play, and how we organize ourselves.
Frequently Asked Questions About PRGO
Did PRGO beat earnings estimates last quarter?
Yes. Perrigo Company reported EPS of $0.60 for the quarter ended Sep 30, 2026, above the $0.56 estimate, a 7.14% surprise.
What EPS do analysts expect from PRGO next quarter?
The consensus EPS estimate for Perrigo Company for the quarter ending Dec 31, 2026 is $0.77 from 5 analysts, with estimates from $0.73 to $0.81.
How often does PRGO beat earnings estimates?
Perrigo Company beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +6.23%.
PRGO pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors